Clinuvel Pharmaceuticals Ltd. (CUVL) Gamma Exposure (GEX) & Greeks

Gamma exposure (GEX) analysis shows how options positioning creates dealer hedging pressure across strikes. Includes delta, vanna, charm, vomma, and vega exposure by strike price.

Clinuvel Pharmaceuticals Ltd. (CUVL) operates in the Healthcare sector, specifically the Medical - Pharmaceuticals industry, with a market capitalization near $310.6M, listed on NASDAQ, carrying a beta of 0.57 to the broader market. Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Led by Philippe Jacques Wolgen, public since 2026-07-13.

Greeks exposure analysis shows dealer hedging pressure across strike prices for all six Greeks. No recent options activity for CUVL as of 2026-08-31; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how gamma exposure is reported and how to read the data →